TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03450564

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Women Education
Description: This intervention intends to provide health education message for women enhance FP utilization in pastoralist community. It was cognizant that, Ethiopia is the second most populous country in Africa. And there is a great discrepancy between contraceptive use, unmet need for FP and maternal and child morbidity and mortality between the pastoralist and agrarian community. Pastoralist community in the country expressed as low contraceptive users, a high unmet need for FP and highest maternal and child morbidity and mortality. The previous study indicates that only 5.4% of the women use contraceptive. The most common reason mentioned for not using of contraceptive are lack of awareness, demand for a large number of children and male dominance in all decision making power in general and FP in particular. In light of this, the study hypothesized that working with men and educating women towards the use of FP could enhance the use of family planning utilization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Male Involvement
Description: Male involvement was a feature of intervention in this arm. Comprehensive health education about FP was given in addition to the video message about FP. In pastoralist community the most reason mentioned for not using of FP are husband objection and religion influence. And most of the decisions are in the palm of husband to seek care for reproductive, maternal and neonatal health in general and FP in particular. Besides, the pastoralist community manifested by high total fertility rate and maternal and child morbidity and mortality.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The third group in this community based intervention was following the community without provision of male iand married women education. In this group there was no intervention by the researchers. However, the activities performed by the government about family planning provision was maintained.
Study: NCT03179345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05240196

Intervention type: OTHER
Group type: OTHER
Intervention: music
Description: playing binaural or non-binaural music

Intervention type: OTHER
Group type: OTHER
Intervention: music
Description: playing binaural or non-binaural music
Study: NCT03110003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg Bupivacaine
Description: 10 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl injected to the epidural space

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mg Bupivacaine
Description: 5 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl in combination with 10 mL of sterile saline injected into the epidural space.
Study: NCT03654625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Written Exposure
Description: Four spaced, 30-minute sessions occurring within a period of 2 weeks. Participants write a narrative about their worst worry.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Written Exposure
Description: Four spaced, 30-minute sessions occurring within a period of 2 weeks. Participants write a narrative about their worst worry and rescript it.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Condition
Description: Four spaced, 30-minute sessions occurring within a period of 2 weeks. At each session, participants write a narrative about a neutral topic.
Study: NCT00488748

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thymatron
Description: Right unilateral placement, 6x seizure threshold, 3 times per week until clinically appropriate to stop (approximately 2-6 weeks)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim Theta
Description: 100% power, vertex placement, 3 times per week, until clinically appropriate to stop (approximately 2-6 weeks)
Study: NCT02003053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Trainer

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inspiratory Muscle Trainer
Study: NCT02084004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium viable pharmaceutics

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine Hydrochloride
Study: NCT02750124

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cobas PCR Female swab sample Packet
Description: The cobas® PCR Female Swab Sample Kit is used to collect and transport vaginal swab specimens self-collected.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cobas PCR Female swab sample Packet
Description: The cobas® PCR Female Swab Sample Kit is used to collect and transport vaginal swab specimens self-collected.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cobas PCR Female swab sample Packet
Description: The cobas® PCR Female Swab Sample Kit is used to collect and transport vaginal swab specimens self-collected.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine practice
Description: The standard, annual renewed invitation to cervical screening.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine practice
Description: The standard, annual renewed invitation to cervical screening.
Study: NCT02252731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-4592
Description: Oral
Study: NCT01022047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noex
Description: The patients shall use the Noex drug only once a day (one application in each nostril) during the 12 weeks of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budecort Aqua
Description: The patients shall use the Budecort Aqua drug only once a day (one application in each nostril) during the 12 weeks of treatment.
Study: NCT02529280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Intervention includes 1) a 30-minute computer-based video (in English/Spanish), featuring instructional screens, graphics and animation to help participants understand the concepts presented. It will feature breast cancer patients who have participated in CTs, patients talking to their doctor or nurse and a bilingual narrator to guide participants. Video content will address common barriers and concerns regarding clinical trials, as well as the informed consent process, and how clinical trials are monitored and reviewed; 2) a bilingual easy to understand booklet with tailored information on clinical trials. The booklet will include many of the elements and messages featured in the video program; and 3) assistance from a trained, bilingual, bicultural, nurse navigator.
Study: NCT02758665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Study: NCT01513070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quick-Acting Heart Reliever
Description: Quick-Acting Heart Reliever，200mg，tid，po. for six months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: Isosorbide Dinitrate，10mg，tid，po. for six months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Isosorbide Dinitrate
Description: Placebo of Isosorbide Dinitrate，10mg，tid，po. for six months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Enteric-coated Tablets
Description: Aspirin Enteric-coated Tablets，100mg，qd，po. for six months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Quick-Acting Heart Reliever
Description: Placebo of Quick-Acting Heart Reliever，200mg，tid，po. for six months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin Enteric-coated Tablets
Description: Aspirin Enteric-coated Tablets，100mg，qd，po. for six months
Study: NCT02194998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)
Description: PTV/r/OBT: 150/100/25 mg (two 75/50/12.5 mg fixed-dose combination tablets) orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)
Description: PTV/r/OBT: 150/100/25 mg (two 75/50/12.5 mg fixed-dose combination tablets) orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)
Description: PTV/r/OBT: 150/100/25 mg (two 75/50/12.5 mg fixed-dose combination tablets) orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)
Description: PTV/r/OBT: 150/100/25 mg (two 75/50/12.5 mg fixed-dose combination tablets) orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir (DSV)
Description: DSV: 250 mg orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir (DSV)
Description: DSV: 250 mg orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir (DSV)
Description: DSV: 250 mg orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir (DSV)
Description: DSV: 250 mg orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: RBV: 1,000 or 1,200 mg (weight-based) dosed in two divided doses orally twice a day (all participants (version 1); only participants with HCV genotype 1a (version2))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: RBV: 1,000 or 1,200 mg (weight-based) dosed in two divided doses orally twice a day (all participants (version 1); only participants with HCV genotype 1a (version2))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: RBV: 1,000 or 1,200 mg (weight-based) dosed in two divided doses orally twice a day (all participants (version 1); only participants with HCV genotype 1a (version2))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: RBV: 1,000 or 1,200 mg (weight-based) dosed in two divided doses orally twice a day (all participants (version 1); only participants with HCV genotype 1a (version2))
Study: NCT01342328

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline infusion
Description: Normal saline infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Infusion of Dexmedetomidine will be administrated during the overnight sleep study. An initial target concentration of 0.25 ng/ml will be selected. After 5 min, the sedative point will be assessed and the concentration will be adjusted stepwise by increments and decrements of 0.05 ng/ml. This process will be repeated until the target sedative state is achieved. Using the Richmond Agitation Sedation Scale (RASS) infusion rates, using known pharmacokinetic parameters will be adjusted to achieve equivalent levels of sedation (RASS -3) for both DEX and propofol sessions.~We aim to achieve an RASS of -3 so that the subjects are moderately sedated. This state of sedation will be maintained for 3-4 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: For propofol, an initial concentration of 0.75 ng/ml will be targeted. Depending on the score achieved, the infusion rate will be increased or decreased every 5 min by 0.2 ng/ml until the target sedative state is achieved.~Note that the target sedative state (RASS score of -3) is the same for both DEX and propofol sessions, with the investigator being unaware of which drug is being administered. To ensure the investigator is not aware of the type of drug being administered, all drug delivery systems will be covered.~Intravenous drug delivery will be continued throughout the scanning period for 3-4 hours to maintain equivalent levels of sedation for both DEX and propofol.
Study: NCT02492568

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Study: NCT00431691

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin and mineral supplement
Description: dose: 4 tablets daily for two weeks~vitamin A 7160 IU, vitamin C 113mg, vitamin E 100IU, zinc 17.4mg, copper 0.4mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escherichia coli Endotoxin (LPS)
Description: dose: 2 ng/kg (corresponding to 20 IU/kg), intravenous bolus over 5 minutes on both study days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escherichia coli Endotoxin (LPS)
Description: dose: 2 ng/kg (corresponding to 20 IU/kg), intravenous bolus over 5 minutes on both study days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100% O2
Description: breathing for 30 minutes, 2 breathing periods on both study days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 100% O2
Description: breathing for 30 minutes, 2 breathing periods on both study days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroglycerin
Description: dose: 0,8 mg sublingual, applied during FMD measurements on both study days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nitroglycerin
Description: dose: 0,8 mg sublingual, applied during FMD measurements on both study days
Study: NCT00477347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed loop administration
Description: intraoperative closed loop administration of propofol and remifentanil

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual administration
Description: intraoperative manual administration of propofol and remifentanil
Study: NCT03622138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Impact
Description: Impact is an easy to use, cost- and time-efficient technology platform that is capable of (a) gathering relevant process and outcomes data in a feasible way within real-world service settings; (b) producing real-time analytics (e.g., graphical displays) and meaningful reports at the provider, service setting, and broader levels (e.g., state-wide); and (c) linking data analytics to continuous quality improvement (CQI) feedback to help providers achieve best practices and targeted youth outcomes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Impact
Description: Impact is an easy to use, cost- and time-efficient technology platform that is capable of (a) gathering relevant process and outcomes data in a feasible way within real-world service settings; (b) producing real-time analytics (e.g., graphical displays) and meaningful reports at the provider, service setting, and broader levels (e.g., state-wide); and (c) linking data analytics to continuous quality improvement (CQI) feedback to help providers achieve best practices and targeted youth outcomes.
Study: NCT02011178

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical treatment and surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Optimal medical treatment
Study: NCT03866694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRIGHT
Description: Dyadic therapeutic parenting intervention (BRIGHT) beginning in third trimester of pregnancy through six months postpartum focusing on child-parent relationship, mental health, infant social-emotional development, and recovery. Monthly handouts for mothers in recovery with information about child development and recovery from substance misuse while parenting and the standard of care at participant's high risk maternal-fetal medical clinic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STAR/TAU+
Description: Monthly handouts for mothers in recovery with information about child development and recovery from substance misuse while parenting and the standard of care at participant's high risk maternal-fetal medical clinic
Study: NCT02754453

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral lifestyle intervention
Description: 20 session lifestyle behavioral intervention with the goal of altering diet and physical activity and decreasing problematic behaviors associated with weight regain and session behavioral intervention addressing increasing physical activity, improving adherence to dietary recommendations and altering problematic eating behaviors.
Study: NCT00626145

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: saline infusion
Description: Patients receive intracoronary injections of saline 7 days after PCI.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow mononuclear cells infusion
Description: Patients receive intracoronary injections of autologous bone marrow mononuclear cells 7 days after PCI.
Study: NCT01093417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D 4000 IU will be administered to enrollees on the active comparator arm

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills will be administered to enrollees in this arm
Study: NCT02805738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-390
Description: CKD-390 1 Tablet (48 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: viread
Description: viread1 Tablet (24 weeks), CKD-390 1 Tablet (from 24 weeks to 48 weeks)
Study: NCT02747927

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TDV placebo-matching SC injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent Dengue Vaccine (TDV)
Description: TDV SC injection.
Study: NCT01807208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Tool
Description: A personalized health goal education and reminder tool, with 3 parts: report card showing the status of secondary prevention domains during hospitalization; questions to help prepare the patient for the follow-up visit; and potential questions for the physician.
Study: NCT03056781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social interaction
Description: Participants will engage in a social interaction with another person

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: food consumption
Description: Participants will be offered food stuffs to eat/drink
Study: NCT01621022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion + nicotine gum
Description: 150 mg bupropion twice daily plus 4 mg nicotine gum as needed (up to 12 pcs/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active bupropion-Placebo gum
Description: 150mg bupropion twice daily plus placebo nicotine gum as needed (up to 12 pcs/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo bupropion-Placebo gum
Description: Placebo bupropion twice daily + placebo nicotine gum as needed (up to 12 pcs/day)
Study: NCT01659203

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IG-IMPT
Description: Daily, Monday-Friday for about 6 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IG IMRT
Description: Daily, Monday-Friday for about 6 weeks
Study: NCT03287609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab 140 mg/mL
Description: Three injections with pre-filled auto-injector pen at day 1 and at week 4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three injections with pre-filled auto-injector pen at day 1 and at week 4.
Study: NCT00991445

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Invasive Surgery
Description: After a 8-10 cm skin incision, a medial parapatellar capsule incision is made. The vastus medialis muscle or the rectus tendon are not incised, nor is the patella everted. The patella is merely pushed slightly aside when the bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exposure
Description: After a 15-20 cm midline skin incision is made, a medial parapatellar capsule incision is made. The incision is carried up through the insertion of the vastus medialis and into the rectus tendon. The patella is everted. The bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.
Study: NCT03388307

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unilateral laminotomy
Description: minimally invasive technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: decompressive laminectomy
Description: classic surgery
Study: NCT01449071

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusions at study weeks 0, 1, 2, and 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab 400 mg
Description: Epratuzumab 400 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab 1200 mg
Description: Epratuzumab 1200 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab 100 mg
Description: Epratuzumab 100 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab 600 mg
Description: Epratuzumab 600 mg infusions at study weeks 0, 1, 2, and 3.
Study: NCT02024087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalantercept plus sorafenib
Description: Subcutaneous (SC) injection of dalantercept once every 3 weeks and oral sorafenib daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalantercept plus sorafenib
Description: Subcutaneous (SC) injection of dalantercept once every 3 weeks and oral sorafenib daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalantercept plus sorafenib
Description: Subcutaneous (SC) injection of dalantercept once every 3 weeks and oral sorafenib daily.
Study: NCT00189709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluconazole
Description: IV
Study: NCT00929500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAST program
Description: MAST program: twice a week for 4 months
Study: NCT00613470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram and escitalopram
Description: escitalopram tablets starting at 10 mg, increase to 20 mg at 4 weeks if QIDS-C16 \> 5, keep at same dose if QIDS-C16 \< 5.~citalopram tablet or solution starting at 2o mg, increase to 40 mg at 4 weeks if QIDS-C16 \> 5, keep at same dose if QIDS-C16 \< 5.